Answers are grounded in this paper and cite their sources.
Transplant-associated thrombotic microangiopathy (TA-TMA) has evolved from a poorly understood and frequently fatal complication of hematopoietic stem cell transplantation (HSCT) into the leading clinical model for precision complement therapeutics. Studies of TA-TMA have established endothelial injury and complement dysregulation as clinically actionable mechanisms and demonstrated that successful complement inhibition requires more than selecting an effective therapeutic agent. Longitudinal pharmacokinetic/pharmacodynamic (PK/PD)-guided dosing, durable terminal complement blockade, and integration of biomarkers reflecting complement activation, endothelial injury, inflammation, and organ dysfunction have transformed eculizumab into the first example of individualized complement-directed therapy in transplantation. Beyond improving outcomes in patients with TA-TMA, these advances have fundamentally changed our understanding of post-transplant endothelial injury, revealing shared biological pathways across multiple transplant-associated complications and supporting a transition from syndrome-based to mechanism-based clinical management. The expanding availability of eculizumab biosimilars and complement pathway-specific inhibitors, including lectin pathway inhibition, further broadens opportunities for personalized therapeutic strategies while emphasizing the need for harmonized diagnostic criteria, standardized response assessment, and biomarker-guided patient selection. Together, the lessons learned from TA-TMA provide a framework for future precision complement therapeutics in transplantation and illustrate how mechanistic understanding of disease biology can transform clinical practice.
No takes yet. Share an insight, caveat, or question.
Sonata Jodele (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: